Get a glimpse into our company and investor data—powered by the PitchBook Platform
Inhibitor Therapeutics Inc, formerly HedgePath Pharmaceuticals Inc is a pharmaceutical development company focused on developing and commercializing therapies for patients with cancer and non-cancerous proliferation disorders. The company's main focus is to advance its lead product, SUBA-Itraconazole a patented, oral formulation of the currently marketed, well-understood, anti-fungal drug, Itraconazole, for prostate and lung cancer.
You’re viewing a free company profile from the PitchBook Platform. To explore INHIBITOR Therapeutics’s full profile, request a free trial.
52 wk Range | Market Cap | Prev. Close | EPS | Average Volume | Shares |
---|---|---|---|---|---|
$14.1M | $0.05 | -$0.01 | 18.4K | 370M |
In Thousands,
USD |
TTM
30-Sep-2019
|
FY 2018
31-Dec-2018
|
FY 2017
31-Dec-2017
|
FY 2016
31-Dec-2016
|
---|---|---|---|---|
Enterprise Value | 24,237 | 24,718 | 91,882 | 134,277 |
Revenue | 0 | 0 | 0 | 0 |
EBITDA | (3,440) | (4,564) | (5,119) | (7,022) |
Net Income | (3,424) | (4,550) | (5,101) | (7,000) |
Total Assets | 1,484 | 1,233 | 768 | 7,338 |
Total Debt | 0 | 0 | 0 | 0 |
Deal Type | Date | Amount | Post-Val | Valuation/ EBITDA |
Debt | Status |
---|
This information is reserved for PitchBook Platform users. To explore INHIBITOR Therapeutics‘s full profile, request access.
Request full access to PitchBookCompany Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
---|---|---|---|---|---|---|
Ra Pharmaceuticals | Formerly VC-backed | Cambridge, MA | 00 | 00000 | 000000&0 | 00000 |
0000000 0000000000 | Formerly VC-backed | Dallas, TX | 00 | 00000 | 000000&0 | 00000 |
00000 000000000000 | Corporate Backed or Acquired | Carlsbad, CA | 000 | 0000 | 00000000000 | 0000 |
000000 00000000 | Formerly VC-backed | Foster City, CA | 00000 | 00.000 | 000000000 | 00.000 |
0000000 0000000000 | Corporation | San Diego, CA | 00 | 00000 | 000000000 | 00000 |
Investor Name | Investor Type | Holding | Participating Rounds | Investor Since | Board Seat | Contact Info |
---|
This information is reserved for PitchBook Platform users. To explore INHIBITOR Therapeutics‘s full profile, request access.
Request full access to PitchBookName | Title | Board Seat |
Contact Info |
---|---|---|---|
Nicholas Virca | President and Chief Executive Officer | ||
Garrison Hasara | Chief Financial Officer and Treasurer | ||
James McNulty | Secretary, Compliance Officer and Treasurer |
Name | Representing | Role | Since | Contact Info |
---|---|---|---|---|
000000 00000 00. | INHIBITOR Therapeutics | Board Member | 000 0000 |